Inflammatory Muscle Injury During Critical Illness: Pathogenesis, Diagnosis, and Clinical Management

Abstract

Inflammatory muscle injury, commonly manifesting as critical illness myopathy (CIM) and myositis, is a significant complication in critically ill patients, particularly those requiring prolonged intensive care. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical features, diagnostic strategies, and management of inflammatory muscle injury during critical illness, with an emphasis on recent advances and guideline-based recommendations for optimal patient outcomes.

Introduction

Muscle injury arising from inflammation during critical illness presents a formidable clinical challenge, with profound implications for morbidity and mortality. The spectrum includes CIM and other inflammatory myopathies, collectively contributing to prolonged mechanical ventilation, delayed rehabilitation, and increased healthcare burden. Understanding the mechanisms, risk factors, and evolving management strategies is vital for intensive care physicians, neurologists, and rehabilitation specialists.

Epidemiology / Disease Burden

The prevalence of inflammatory muscle injury among critically ill patients, particularly those with sepsis, multi-organ failure, or prolonged immobilization, ranges from 25% to 60% in various cohorts. CIM is frequently underdiagnosed, yet autopsy and electromyography studies suggest subclinical involvement is even more common. In recent years, the COVID-19 pandemic has further highlighted the burden of inflammatory muscle injury, with reports of viral-induced myopathies and exacerbation of critical illness neuropathy. The resultant weakness not only impedes weaning from mechanical ventilation but also prolongs intensive care and hospital stays, escalating healthcare costs and impacting long-term quality of life.

Pathophysiology

The pathogenesis of inflammatory muscle injury during critical illness is multifactorial, involving systemic and local mechanisms. Systemic inflammation is characterized by elevated cytokines (e.g., TNF-α, IL-1β, IL-6) and oxidative stress, which disrupt muscle protein synthesis and augment proteolysis via the ubiquitin-proteasome pathway. Microvascular dysfunction, mitochondrial impairment, and altered excitation-contraction coupling further compound muscle injury. Direct muscle invasion by pathogens, particularly in viral infections, can precipitate myositis. Critical illness itself induces hormonal derangements (e.g., insulin resistance, corticosteroid excess) that exacerbate muscle catabolism. Additionally, immobilization leads to muscle disuse atrophy, while pharmacological agents such as corticosteroids and neuromuscular blocking agents potentiate the injury through steroid myopathy and direct myotoxicity, respectively.

Risk Factors

Several risk factors predispose critically ill patients to inflammatory muscle injury. Prolonged mechanical ventilation, severity of sepsis or systemic inflammatory response syndrome, multi-organ dysfunction, hyperglycemia, and extended immobilization are well-established contributors. High-dose corticosteroid therapy, the use of neuromuscular blocking agents, and specific infections (notably viral) further increase susceptibility. Genetic predisposition, underlying neuromuscular disorders, and advanced age also modulate the risk and severity of muscle injury in the intensive care setting.

Clinical Features

Clinically, patients typically present with symmetrical, generalized muscle weakness, often more pronounced in proximal muscle groups. The onset is usually insidious, developing over days to weeks of critical illness. Deep tendon reflexes are preserved or mildly diminished, and sensory function is typically intact, helping to distinguish CIM from critical illness polyneuropathy (CIP). Severe cases can result in quadriplegia and failure to wean from mechanical ventilation. Myalgia and muscle tenderness may be present but are frequently masked by sedation or encephalopathy. Rhabdomyolysis, with consequent elevations in creatine kinase and myoglobinuria, may occur in severe inflammatory myopathies, particularly of viral etiology.

Diagnosis

Diagnosis of inflammatory muscle injury during critical illness is multifaceted, relying on clinical, laboratory, electrophysiological, and histopathological criteria. Laboratory findings include elevated serum creatine kinase and transaminases, though normal values do not exclude myopathy. Electromyography (EMG) reveals myopathic changes—short-duration, low-amplitude motor unit potentials, and early recruitment patterns. Nerve conduction studies help differentiate CIM from CIP. Muscle biopsy, though rarely performed, confirms diagnosis, revealing muscle fiber necrosis, mononuclear infiltrates, and loss of myosin filaments. Imaging modalities, such as MRI, can demonstrate muscle edema and inflammation, aiding in diagnosis where biopsy is impractical. Early recognition is crucial for prognosis and management.

Treatment & Management

Management strategies are primarily supportive, aiming to mitigate further muscle injury and promote functional recovery. Early mobilization and physical rehabilitation are the cornerstones of therapy, shown to attenuate muscle atrophy and improve outcomes. Glycemic control, minimizing the use of corticosteroids and neuromuscular blocking agents, and optimizing nutrition are pivotal. Specific immunomodulatory therapies, such as intravenous immunoglobulin or corticosteroids, may be indicated in biopsy-proven inflammatory myopathies, though evidence is limited and should be individualized. Multidisciplinary care involving intensivists, neurologists, physiotherapists, and nutritionists is essential for comprehensive management.

Recent Advances / Emerging Therapies

Recent research has explored novel therapeutic targets, including selective cytokine inhibitors (e.g., IL-6 antagonists), antioxidants, and agents modulating the ubiquitin-proteasome pathway. Early-phase trials of anabolic agents and myostatin inhibitors show promise in preventing muscle loss, though robust clinical data are pending. Innovations in neuromuscular stimulation and advanced rehabilitation protocols are being integrated into critical care practice. Biomarker discovery, such as serum microRNAs and advanced imaging, may enable earlier detection and targeted therapy in the future. The COVID-19 pandemic has accelerated research into viral-associated myopathies and highlighted the need for vigilance regarding muscle injury in emerging infectious diseases.

Guideline Recommendations

Current guidelines from the Society of Critical Care Medicine and the European Society of Intensive Care Medicine emphasize early recognition, prevention, and rehabilitation as key management principles. Routine neuromuscular assessment, minimization of risk factors, and structured physiotherapy are strongly recommended. The use of corticosteroids should be judicious, reserved for specific indications, and implemented with the lowest effective dose. Regular reassessment of sedative and neuromuscular blockade requirements is advised to mitigate iatrogenic muscle injury. Interdisciplinary collaboration remains central to optimal patient care and functional recovery.

Conclusion

Inflammatory muscle injury during critical illness is a prevalent, yet underrecognized, complication with significant ramifications for patient outcomes. Advances in understanding the underlying mechanisms, improved diagnostic modalities, and the adoption of early rehabilitation strategies have enhanced patient care. Ongoing research into targeted therapies and biomarkers holds promise for the future, but prevention and multidisciplinary management remain the cornerstones of therapy. Vigilance and evidence-based practice are essential for minimizing the burden of muscle injury in the critically ill population.